What Is Vyvanse? Complete Guide to Lisdexamfetamine for ADHD | VyvansePills.com
Complete Guide

What Is Vyvanse?
Everything You Need to Know

Vyvanse (lisdexamfetamine dimesylate) is an FDA-approved, long-acting prescription stimulant for ADHD. This guide covers exactly what it is, how it works in the body, what conditions it treats, every available dosage, side effects, safety considerations, and how it compares to other ADHD medications.

12–14h
Duration per dose
13
Dosage strengths
2007
FDA approval year
6+
Approved age (ADHD)
Drug Profile
Brand NameVyvanse
Generic NameLisdexamfetamine Dimesylate
Drug ClassCNS Stimulant / Prodrug
Active MetaboliteDextroamphetamine
DEA ScheduleSchedule II
FDA Approved2007 (ADHD)
ManufacturerTakeda Pharmaceuticals
Forms AvailableCapsule + Chewable Tablet
Dose Range10mg – 70mg
What is it?
Prodrug CNS stimulant for ADHD
Active ingredient
Lisdexamfetamine Dimesylate
How it works
Converts to dextroamphetamine in blood
Lasts
12–14 hours per dose
Approved for
ADHD (age 6+) & BED (adults)

What Is Vyvanse?

Vyvanse is the brand name for lisdexamfetamine dimesylate — a prescription central nervous system (CNS) stimulant medication manufactured by Takeda Pharmaceuticals. It was first approved by the FDA in 2007 for the treatment of ADHD and has since become one of the most widely prescribed ADHD medications in the United States.

What makes Vyvanse clinically distinct from other stimulants is its classification as a prodrug. When you take Vyvanse, you are not taking an active stimulant compound. You are taking an inactive molecule — lisdexamfetamine — that only becomes pharmacologically active after your body converts it. This conversion happens in red blood cells and proceeds at a gradual, physiologically rate-limited pace.

The result is a medication that provides 12–14 hours of smooth, continuous ADHD symptom control from a single morning dose, without the sharp peaks and crashes associated with immediate-release amphetamines.

2007
Year FDA approved Vyvanse for ADHD
14h
Maximum duration of effect per dose
13
Available dosage strengths (capsule + chewable)
70mg
Maximum FDA-approved daily dose
Key fact: Vyvanse is the brand name — lisdexamfetamine dimesylate is the active ingredient. All products on VyvansePills.com contain lisdexamfetamine dimesylate, the same compound as brand-name Vyvanse, in every FDA-recognized strength.

How Does Vyvanse Work?

Vyvanse works through a two-stage process — first a biological conversion step, then a neurochemical action step. Understanding both helps explain why it behaves so differently from direct-acting stimulants.

The Prodrug Mechanism — Step by Step
1

Ingestion — Inactive Molecule Enters the Body

You take lisdexamfetamine dimesylate once daily in the morning. At this point it is completely pharmacologically inactive — no stimulant effect occurs at ingestion. It can be taken with or without food because gastric pH does not affect its metabolism.

No immediate effect
2

Gastrointestinal Absorption

The inactive lisdexamfetamine molecule is absorbed through the gastrointestinal tract wall into the bloodstream. It circulates in the blood in its inactive form, bound to red blood cells.

Absorbed, still inactive
3

Red Blood Cell Enzymatic Conversion

Red blood cell enzymes — specifically peptidases — gradually cleave the l-lysine amino acid from the lisdexamfetamine molecule. This releases active dextroamphetamine into the blood at a slow, controlled, physiologically rate-limited pace. Because the conversion rate is capped by red blood cell enzyme capacity, it cannot be accelerated — even at higher doses.

Rate-limited release
4

Dopamine & Norepinephrine Increase

Active dextroamphetamine crosses the blood-brain barrier and enters the prefrontal cortex — the brain region responsible for executive function. It increases dopamine and norepinephrine by blocking their reuptake transporters and triggering their release from presynaptic nerve terminals. This elevates the availability of both neurotransmitters at the synapse.

ADHD symptom improvement begins
5

12–14 Hours of Continuous, Stable Coverage

Because conversion is gradual and rate-limited, dextroamphetamine levels rise slowly (onset 1–2 hours), peak steadily (3–5 hours), and decline gradually over 12–14 hours. There is no sudden spike that creates an overstimulated peak, and no sudden drop that creates a harsh crash. Symptom control is continuous and stable through a single morning dose.

No crash
Why this matters for abuse potential: Because lisdexamfetamine is inactive until enzymatically processed through normal red blood cell metabolism, it cannot produce a stimulant effect via alternative routes of administration. This built-in deterrence is why Vyvanse was specifically designed with this prodrug architecture.

What Conditions Does Vyvanse Treat?

Vyvanse has two official FDA-approved indications. Any use outside these two indications is considered off-label and requires individualized physician judgment.

✓ FDA Approved

Attention Deficit Hyperactivity Disorder (ADHD)

Approved for pediatric patients aged 6 and older, adolescents, and adults. ADHD is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that impair functioning across settings. Vyvanse addresses the dopamine and norepinephrine dysregulation underlying these symptoms.

✓ FDA Approved

Moderate-to-Severe Binge Eating Disorder (BED)

Approved for adults only. BED involves recurrent episodes of consuming large quantities of food rapidly and without control, often accompanied by significant distress. Vyvanse is the first and only FDA-approved medication for moderate-to-severe BED. It is not approved for weight loss or obesity treatment.

Off-Label Use

Treatment-Resistant Depression

Some clinicians use lisdexamfetamine as adjunctive therapy in treatment-resistant depression, particularly for fatigue and cognitive symptoms. This is an off-label use and requires specialist oversight.

Off-Label Use

Excessive Daytime Sleepiness / Fatigue

Occasionally used off-label in cancer-related fatigue and narcolepsy-adjacent conditions under specialist supervision. Not approved for these indications and should not be self-prescribed.

Important: Vyvanse is not approved for weight loss, general cognitive enhancement, or as a study aid. Using it for these purposes without a valid ADHD or BED diagnosis and prescription is illegal under federal law.

Vyvanse Dosages & Available Forms

Vyvanse is available in two formulations — oral capsules and chewable tablets — across 13 total dosage strengths. Both formulations contain lisdexamfetamine dimesylate and produce identical therapeutic effects. The choice between them is purely a matter of patient preference and ability to take the medication.

Strength Form Typical Patient Profile Phase Price
10mgCapsule / ChewablePediatric starter; highly sensitive adultsStarterfrom $140.88
20mgCapsule / ChewableStandard starting dose for children & adolescentsStarterfrom $165.88
30mgCapsule / ChewableMost common adult starting doseCommonfrom $195.88
40mgCapsule / ChewableAdult maintenance — titrated from 30mgCommonfrom $225.88
50mgCapsule / ChewableAdult maintenance — higher clinical response neededCommonfrom $260.88
60mgCapsule / ChewableHigher body weight or extended coverage needsHigh Dosefrom $295.88
70mgCapsule onlyMaximum FDA dose — adults requiring full coverageMaximum$410.88

Capsules (10mg–70mg) can be swallowed whole or opened and dissolved in a glass of water — consumed immediately. This makes them suitable for patients who prefer to swallow a pill or need a liquid option.

Chewable tablets (10mg–60mg) must be chewed thoroughly before swallowing — they should not be swallowed whole. They are flavoured and particularly preferred by children or adults who have difficulty swallowing capsules. Note that the chewable range tops out at 60mg; the 70mg maximum dose is only available as a capsule.

Titration: Dosing is always started at the lowest appropriate dose and increased in 10mg or 20mg increments weekly based on clinical response and tolerability. Never self-adjust your dose. Your prescriber will determine the optimal maintenance dose for your individual situation.

Vyvanse Side Effects

Like all CNS stimulants, Vyvanse produces a range of possible side effects. Most common side effects occur predominantly during the initial titration period and often reduce in intensity as the body adjusts to the medication.

Common Side Effects

!
Decreased appetite / weight loss
!
Difficulty falling or staying asleep (insomnia)
!
Dry mouth
!
Headache
!
Irritability or emotional lability
!
Increased heart rate and blood pressure
!
Nausea and stomach discomfort
!
Anxiety or restlessness
!
Dizziness

Serious Side Effects — Seek Medical Attention

Chest pain or shortness of breath (cardiovascular)
New or worsening psychosis, hallucinations, mania
Aggressive or hostile behaviour
Serotonin syndrome (when combined with serotonergic drugs)
Peripheral vasculopathy (Raynaud’s phenomenon)
Slowed growth in children — monitor height and weight
Signs of circulation problems in fingers/toes
Suicidal ideation or severe mood changes
Seizures (rare)
Call 911 or go to an emergency department immediately if you experience chest pain, irregular heartbeat, hallucinations, severe agitation, very high body temperature, seizures, or loss of consciousness. These may indicate a serious adverse event requiring immediate medical intervention.

Safety, Warnings & Contraindications

Vyvanse carries a boxed warning — the FDA’s most serious warning level — for high potential for abuse and psychological and physical dependence. This is standard for all Schedule II stimulants and does not mean the medication is unsafe when used as prescribed.

Who should not take Vyvanse:

Patients with known hypersensitivity to amphetamines or lisdexamfetamine
During or within 14 days of MAOI antidepressant therapy (risk of hypertensive crisis)
Patients with serious structural cardiac abnormalities, cardiomyopathy, or serious heart arrhythmias
History of drug abuse or active substance use disorder (use with extreme caution under specialist supervision)
Pregnancy or breastfeeding (consult physician — risk to fetus and nursing infant)

Important drug interactions to discuss with your prescriber before starting Vyvanse include: MAOIs, SSRIs/SNRIs (serotonin syndrome risk), blood pressure medications (Vyvanse raises BP), antiacids (may alter absorption timing), and other stimulants.

Schedule II status: Vyvanse requires a new written prescription for each fill. Automatic refills are prohibited by federal law. Your prescriber must issue a new prescription every 30 days. Keep Vyvanse in a secure location — misuse of prescription stimulants is a federal offense.

Vyvanse vs Other ADHD Medications

Vyvanse is one of several long-acting stimulants used for ADHD. Here is how it compares to the two most commonly prescribed alternatives.

Vyvanse (Lisdexamfetamine)

12–14 hour duration — longest available
Prodrug — built-in abuse deterrence
Smooth onset, minimal crash
Unaffected by food or gastric pH
Chewable form available
vs

Adderall XR (Mixed Amphetamine Salts)

8–12 hours duration
Active compound — faster onset
More pronounced afternoon rebound
Absorption affected by acidic food/drink
Lower cost (generic widely available)

For a detailed, section-by-section comparison of Vyvanse and Adderall — covering mechanism, duration, side effects, cost, dose conversion, and who each is best suited for — see the full Vyvanse vs Adderall comparison guide →

Frequently Asked Questions About Vyvanse

Yes. Vyvanse is a Schedule II prescription CNS stimulant. It works by increasing the availability of dopamine and norepinephrine in the prefrontal cortex. It is classified in the amphetamine drug family. While its prodrug structure makes it behave differently from direct-acting stimulants in terms of onset and duration, its underlying pharmacological action is stimulant in nature.
Vyvanse’s therapeutic effects last 12–14 hours per dose. The active metabolite dextroamphetamine is detectable in urine for approximately 2–4 days after the last dose and in blood for approximately 24–48 hours. Hair follicle testing can detect amphetamine use for up to 90 days. Detection windows extend with chronic high-dose use. Patients with valid prescriptions should inform testing administrators before any drug screen.
Vyvanse is a central nervous system (CNS) stimulant of the amphetamine class. More specifically, it is a prodrug — meaning it is pharmacologically inactive until metabolized in the body into its active form, dextroamphetamine. It is classified as a DEA Schedule II controlled substance, reflecting its accepted medical use alongside high abuse and dependence potential.
Vyvanse is not FDA-approved for depression or anxiety. In fact, anxiety is a potential side effect of Vyvanse, and for patients with comorbid anxiety disorder, stimulants can worsen anxious symptoms. Some clinicians use lisdexamfetamine off-label as an adjunct in treatment-resistant depression — but only under specialist supervision in carefully selected patients. Never use Vyvanse to self-treat depression or anxiety.
Vyvanse carries a risk of psychological and physical dependence — this is why it is classified as Schedule II. That said, when taken as prescribed by patients with genuine ADHD diagnoses, the clinical evidence suggests that stimulant use in ADHD actually reduces (rather than increases) the risk of substance use disorders. The risk of dependency is highest when Vyvanse is used at doses higher than prescribed, more frequently than prescribed, or by individuals without an ADHD diagnosis. Always use exactly as directed by your prescriber.
No — Vyvanse has a gradual onset of 1–2 hours after ingestion. This is because it must first be absorbed and then converted from inactive lisdexamfetamine into active dextroamphetamine by red blood cell enzymes. Patients who take it and feel “nothing” in the first 30–60 minutes are experiencing the medication working correctly. Effects are typically noticeable within 1–2 hours and reach their peak around 3–5 hours after ingestion.
Yes. Vyvanse is FDA-approved for ADHD in adults as well as children aged 6 and older. In adults, the typical starting dose is 30mg once daily, titrated in 10–20mg increments weekly up to a maximum of 70mg per day. Adults with ADHD represent a substantial and growing proportion of Vyvanse prescriptions.

Shop Vyvanse — All 13 Strengths In Stock

Lisdexamfetamine dimesylate oral capsules 10mg to 70mg and chewable tablets 10mg to 60mg. Discreet shipping, secure checkout, full clinical product documentation.

Medical Disclaimer: This page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Vyvanse (lisdexamfetamine dimesylate) is a DEA Schedule II controlled substance requiring a valid prescription. Always consult a licensed healthcare provider before starting, adjusting, or stopping any prescription medication. Side effect and safety information provided here is not exhaustive — refer to the full prescribing information and your pharmacist for complete details.